{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T23:26:54Z","timestamp":1791588414151,"version":"4.3.4"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"3-4","license":[{"start":{"date-parts":[[2021,1,17]],"date-time":"2021-01-17T00:00:00Z","timestamp":1610841600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,1,17]],"date-time":"2021-01-17T00:00:00Z","timestamp":1610841600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Gene Ther"],"published-print":{"date-parts":[[2023,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Von Willebrand disease (VWD), the most common inherited bleeding disorder in humans, is caused by quantitative or qualitative defects in von Willebrand factor (VWF). VWD represents a potential target for gene therapy applications, as a single treatment could potentially result in a long-term correction of the disease. In recent years, several liver-directed gene therapy approaches have been exploited for VWD, but their efficacy was generally limited by the large size of the VWF transgene and the reduced hemostatic activity of the protein produced from hepatocytes. In this context, we aimed at developing a gene therapy strategy for gene delivery into endothelial cells, the natural site of biosynthesis of VWF. We optimized an endothelial-specific dual hybrid AAV vector, in which the large VWF cDNA was put under the control of an endothelial promoter and correctly reconstituted upon cell transduction by a combination of <jats:italic>trans-<\/jats:italic>splicing and homologous recombination mechanisms. In addition, we modified the AAV vector capsid by introducing an endothelial-targeting peptide to improve the efficiency for endothelial-directed gene transfer. This vector platform allowed the reconstitution of full-length VWF transgene both in vitro in human umbilical vein endothelial cells and in vivo in VWD mice, resulting in long-term expression of VWF.<\/jats:p>","DOI":"10.1038\/s41434-020-00218-6","type":"journal-article","created":{"date-parts":[[2021,1,17]],"date-time":"2021-01-17T11:02:19Z","timestamp":1610881339000},"page":"245-254","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":40,"title":["Development of a dual hybrid AAV vector for endothelial-targeted expression of von Willebrand factor"],"prefix":"10.1038","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5216-817X","authenticated-orcid":false,"given":"Elena","family":"Barbon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charlotte","family":"Kawecki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Solenne","family":"Marmier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aboud","family":"Sakkal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fanny","family":"Collaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Severine","family":"Charles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Ronzitti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8271-6795","authenticated-orcid":false,"given":"Caterina","family":"Casari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivier D.","family":"Christophe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5152-9156","authenticated-orcid":false,"given":"C\u00e9cile V.","family":"Denis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter J.","family":"Lenting","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0685-3752","authenticated-orcid":false,"given":"Federico","family":"Mingozzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,1,17]]},"reference":[{"key":"218_CR1","doi-asserted-by":"publisher","first-page":"2019","DOI":"10.1182\/blood-2014-06-528406","volume":"125","author":"PJ Lenting","year":"2015","unstructured":"Lenting PJ, Christophe OD, Denis CV. Von Willebrand factor biosynthesis, secretion, and clearance: connecting the far ends. Blood. 2015;125:2019\u201328.","journal-title":"Blood"},{"key":"218_CR2","doi-asserted-by":"crossref","unstructured":"Bryckaert M, Rosa JP, Denis CV, Lenting PJ. Of von Willebrand factor and platelets. Cell Mol Life Sci. 2015;72:307\u201326.","DOI":"10.1007\/s00018-014-1743-8"},{"key":"218_CR3","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1038\/279636a0","volume":"279","author":"KS Sakariassen","year":"1979","unstructured":"Sakariassen KS, Bolhuis PA, Sixma JJ. Human blood platelet adhesion to artery subendothelium is mediated by factor VIII-Von Willebrand factor bound to the subendothelium. Nature. 1979;279:636\u20138.","journal-title":"Nature"},{"key":"218_CR4","doi-asserted-by":"publisher","first-page":"21948","DOI":"10.1016\/S0021-9258(18)54729-3","volume":"266","author":"RJ Wise","year":"1991","unstructured":"Wise RJ, Dorner AJ, Krane M, Pittman DD, Kaufman RJ. The role of von Willebrand factor multimers and propeptide cleavage in binding and stabilization of factor VIII. J Biol Chem. 1991;266:21948\u201355.","journal-title":"J Biol Chem"},{"key":"218_CR5","doi-asserted-by":"crossref","unstructured":"Sadler JE. Biochemistry and genetics of von Willebrand factor. Annu Rev Biochem. 1998;67:395\u2013424.","DOI":"10.1146\/annurev.biochem.67.1.395"},{"key":"218_CR6","doi-asserted-by":"crossref","unstructured":"Sadler JE, Mannucci PM, Berntorp E, Bochkov N, Boulyjenkov V, Ginsburg D, et al. Impact, diagnosis and treatment of von Willebrand disease. Thromb Haemost. 2000;84:160\u201374.","DOI":"10.1055\/s-0037-1613992"},{"key":"218_CR7","doi-asserted-by":"crossref","unstructured":"Leebeek FWG, Eikenboom JCJ. Von Willebrand\u2019s disease. N Engl J Med. 2016;375:2067\u201380.","DOI":"10.1056\/NEJMra1601561"},{"key":"218_CR8","doi-asserted-by":"publisher","first-page":"2103","DOI":"10.1111\/j.1538-7836.2006.02146.x","volume":"4","author":"JE Sadler","year":"2006","unstructured":"Sadler JE, Budde U, Eikenboom JCJ, Favaloro EJ, Hill FGH, Holmberg L, et al. Update on the pathophysiology and classification of von Willebrand disease: a report of the subcommittee on von Willebrand factor. J Thromb Haemost. 2006;4:2103\u201314.","journal-title":"J Thromb Haemost"},{"key":"218_CR9","doi-asserted-by":"publisher","first-page":"5049","DOI":"10.1182\/blood-2008-10-165621","volume":"113","author":"SF De Meyer","year":"2009","unstructured":"De Meyer SF, Deckmyn H, Vanhoorelbeke K. Von Willebrand factor to the rescue. Blood. 2009;113:5049\u201357.","journal-title":"Blood"},{"key":"218_CR10","doi-asserted-by":"publisher","first-page":"2038","DOI":"10.1182\/blood-2015-02-629873","volume":"126","author":"JC Gill","year":"2015","unstructured":"Gill JC, Castaman G, Windyga J, Kouides P, Ragni M, Leebeek FWG, et al. Hemostatic efficacy, safety, and pharmacokinetics of a recombinant von Willebrand factor in severe von Willebrand disease. Blood. 2015;126:2038\u201346.","journal-title":"Blood"},{"key":"218_CR11","doi-asserted-by":"publisher","first-page":"3481","DOI":"10.1182\/bloodadvances.2019000368","volume":"3","author":"PM Mannucci","year":"2019","unstructured":"Mannucci PM. New therapies for von Willebrand disease. Blood Adv. 2019;3:3481\u20137.","journal-title":"Blood Adv"},{"key":"218_CR12","doi-asserted-by":"crossref","unstructured":"Lenting PJ, Van Schooten CJM, Denis CV. Clearance mechanisms of von Willebrand factor and factor VIII. J Thromb Haemost. 2007;5:1353\u201360.","DOI":"10.1111\/j.1538-7836.2007.02572.x"},{"key":"218_CR13","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1159\/000338208","volume":"128","author":"AB Federici","year":"2012","unstructured":"Federici AB, James P. Current management of patients with severe von willebrand disease type 3: a 2012 update. Acta Haematol. 2012;128:88\u201399.","journal-title":"Acta Haematol"},{"key":"218_CR14","first-page":"1163","volume":"25","author":"AC Nathwani","year":"2017","unstructured":"Nathwani AC, Davidoff AM, Tuddenham EGD. Gene therapy for hemophilia. Hematol\/Oncol Clinics N Am. 2017;25:1163\u20137.","journal-title":"Hematol\/Oncol Clinics N Am"},{"key":"218_CR15","doi-asserted-by":"publisher","first-page":"4728","DOI":"10.1182\/blood-2005-09-3605","volume":"107","author":"SF De Meyer","year":"2006","unstructured":"De Meyer SF, Vanhoorelbeke K, Chuah MK, Pareyn I, Gillijns V, Hebbel RP, et al. Phenotypic correction of von Willebrand disease type 3 blood-derived endothelial cells with lentiviral vectors expressing von Willebrand factor. Blood. 2006;107:4728\u201336.","journal-title":"Blood"},{"key":"218_CR16","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1161\/ATVBAHA.107.159442","volume":"28","author":"I Marx","year":"2008","unstructured":"Marx I, Lenting PJ, Adler T, Pendu R, Christophe OD, Denis CV. Correction of bleeding symptoms in von Willebrand factor-deficient mice by liver-expressed von Willebrand factor mutants. Arterioscler Thromb Vasc Biol. 2008;28:419\u201324.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"218_CR17","doi-asserted-by":"publisher","first-page":"576","DOI":"10.1089\/hum.2011.238","volume":"23","author":"L Wang","year":"2012","unstructured":"Wang L, Rosenberg JB, De BP, Ferris B, Wang R, Rivella S, et al. In vivo gene transfer strategies to achieve partial correction of von willebrand disease. Hum Gene Ther. 2012;23:576\u201388.","journal-title":"Hum Gene Ther"},{"key":"218_CR18","doi-asserted-by":"publisher","first-page":"1621","DOI":"10.1161\/ATVBAHA.108.168369","volume":"28","author":"SF De Meyer","year":"2008","unstructured":"De Meyer SF, Vandeputte N, Pareyn I, Petrus I, Lenting PJ, Chuah MKL, et al. Restoration of plasma von willebrand factor deficiency is sufficient to correct thrombus formation after gene therapy for severe von willebrand disease. Arterioscler Thromb Vasc Biol. 2008;28:1621\u20136.","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"218_CR19","doi-asserted-by":"publisher","first-page":"592","DOI":"10.1111\/jth.13938","volume":"16","author":"I Portier","year":"2018","unstructured":"Portier I, Vanhoorelbeke K, Verhenne S, Pareyn I, Vandeputte N, Deckmyn H, et al. High and long-term von Willebrand factor expression after sleeping beauty transposon-mediated gene therapy in a mouse model of severe von Willebrand disease. J Thromb Haemost. 2018;16:592\u2013604.","journal-title":"J Thromb Haemost"},{"key":"218_CR20","doi-asserted-by":"publisher","first-page":"9524","DOI":"10.1073\/pnas.95.16.9524","volume":"95","author":"C Denis","year":"1998","unstructured":"Denis C, Methia N, Frenette PS, Rayburn H, Ullman-Culler\u00e9 M, Hynes RO, et al. A mouse model of severe von Willebrand disease: defects in hemostasis and thrombosis. Proc Natl Acad Sci USA. 1998;95:9524\u20139.","journal-title":"Proc Natl Acad Sci USA"},{"key":"218_CR21","doi-asserted-by":"publisher","first-page":"6716","DOI":"10.1073\/pnas.97.12.6716","volume":"97","author":"Z Yan","year":"2000","unstructured":"Yan Z, Zhang Y, Duan D, Engelhardt JF. Trans-splicing vectors expand the utility of adeno-associated virus for gene therapy. Proc Natl Acad Sci USA. 2000;97:6716\u201321.","journal-title":"Proc Natl Acad Sci USA"},{"key":"218_CR22","doi-asserted-by":"crossref","unstructured":"Duan D, Yue Y, Engelhardt JF. Expanding AAV packaging capacity with trans-splicing or overlapping vectors: a quantitative comparison. Mol Ther. 2001;4:383\u201391.","DOI":"10.1006\/mthe.2001.0456"},{"key":"218_CR23","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1038\/sj.mt.6300322","volume":"16","author":"A Ghosh","year":"2008","unstructured":"Ghosh A, Yue Y, Lai Y, Duan D. A hybrid vector system expands adeno-associated viral vector packaging capacity in a transgene-independent manner. Mol Ther. 2008;16:124\u201330.","journal-title":"Mol Ther"},{"key":"218_CR24","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1080\/02648725.2007.10648098","volume":"24","author":"A Ghosh","year":"2007","unstructured":"Ghosh A, Duan D. Expanding adeno-associated viral vector capacity: a tale of two vectors. Biotechnol Genet Eng Rev. 2007;24:165\u201377.","journal-title":"Biotechnol Genet Eng Rev"},{"key":"218_CR25","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1002\/emmm.201302948","volume":"6","author":"I Trapani","year":"2014","unstructured":"Trapani I, Colella P, Sommella A, Iodice C, Cesi G, de Simone S, et al. Effective delivery of large genes to the retina by dual AAV vectors. EMBO Mol Med. 2014;6:194\u2013211.","journal-title":"EMBO Mol Med"},{"key":"218_CR26","doi-asserted-by":"publisher","first-page":"450","DOI":"10.1038\/gt.2014.8","volume":"21","author":"P Colella","year":"2014","unstructured":"Colella P, Trapani I, Cesi G, Sommella A, Manfredi A, Puppo A, et al. Efficient gene delivery to the cone-enriched pig retina by dual AAV vectors. Gene Ther. 2014;21:450\u20136.","journal-title":"Gene Ther"},{"key":"218_CR27","doi-asserted-by":"publisher","first-page":"6811","DOI":"10.1093\/hmg\/ddv386","volume":"24","author":"I Trapani","year":"2015","unstructured":"Trapani I, Toriello E, De Simone S, Colella P, Iodice C, Polishchuk EV, et al. Improved dual AAV vectors with reduced expression of truncated proteins are safe and effective in the retina of a mouse model of Stargardt disease. Hum Mol Genet. 2015;24:6811\u201325.","journal-title":"Hum Mol Genet"},{"key":"218_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1089\/hgtb.2015.140","volume":"27","author":"K Chamberlain","year":"2016","unstructured":"Chamberlain K, Riyad JM, Weber T. Expressing transgenes that exceed the packaging capacity of adeno-associated virus capsids. Hum Gene Therapy Methods. 2016;27:1\u201312.","journal-title":"Hum Gene Therapy Methods"},{"key":"218_CR29","doi-asserted-by":"publisher","first-page":"11737","DOI":"10.1074\/jbc.273.19.11737","volume":"273","author":"PJ Cowan","year":"1998","unstructured":"Cowan PJ, Tsang D, Pedic CM, Abbott LR, Shinkel TA, D\u2019Apice AJF, et al. The human ICAM-2 promoter is endothelial cell-specific in vitro and in vivo and contains critical Sp1 and GATA binding sites. J Biol Chem. 1998;273:11737\u201344.","journal-title":"J Biol Chem"},{"key":"218_CR30","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1038\/gt.2011.143","volume":"19","author":"K Varadi","year":"2012","unstructured":"Varadi K, Michelfelder S, Korff T, Hecker M, Trepel M, Katus HA, et al. Novel random peptide libraries displayed on AAV serotype 9 for selection of endothelial cell-directed gene transfer vectors. Gene Ther. 2012;19:800\u20139.","journal-title":"Gene Ther"},{"key":"218_CR31","doi-asserted-by":"publisher","first-page":"16049","DOI":"10.1038\/mtm.2016.49","volume":"3","author":"G Ronzitti","year":"2016","unstructured":"Ronzitti G, Bortolussi G, van Dijk R, Collaud F, Charles S, Leborgne C, et al. A translationally optimized AAV-UGT1A1 vector drives safe and long-lasting correction of Crigler-Najjar syndrome. Mol Ther - Methods Clin Dev. 2016;3:16049.","journal-title":"Mol Ther - Methods Clin Dev"},{"key":"218_CR32","doi-asserted-by":"publisher","first-page":"5755","DOI":"10.1093\/nar\/19.20.5755","volume":"19","author":"MW Mcburney","year":"1991","unstructured":"Mcburney MW, Sutherland LC, Adra CN, Leclair B, Rudnicki MA, Jardine K. The mouse Pgk-1 gene promoter contains an upstream activator sequence. Nucleic Acids Res. 1991;19:5755\u201361.","journal-title":"Nucleic Acids Res"},{"key":"218_CR33","doi-asserted-by":"publisher","first-page":"503","DOI":"10.1038\/gt.2009.157","volume":"17","author":"E Ayuso","year":"2010","unstructured":"Ayuso E, Mingozzi F, Montane J, Leon X, Anguela XM, Haurigot V, et al. High AAV vector purity results in serotype- and tissue-independent enhancement of transduction efficiency. Gene Ther. 2010;17:503\u201310.","journal-title":"Gene Ther"},{"key":"218_CR34","doi-asserted-by":"publisher","first-page":"12102","DOI":"10.1074\/jbc.M310436200","volume":"279","author":"PJ Lenting","year":"2004","unstructured":"Lenting PJ, Westein E, Terraube V, Ribba AS, Huizinga EG, Meyer D, et al. An experimental model to study the in vivo survival of von Willebrand factor: basic aspects and application to the R1205H mutation. J Biol Chem. 2004;279:12102\u20139.","journal-title":"J Biol Chem"},{"key":"218_CR35","doi-asserted-by":"publisher","first-page":"8568","DOI":"10.1128\/JVI.72.11.8568-8577.1998","volume":"72","author":"D Duan","year":"1998","unstructured":"Duan D, Sharma P, Yang J, Yue Y, Dudus L, Zhang Y, et al. Circular intermediates of recombinant adeno-associated virus have defined structural characteristics responsible for long-term episomal persistence in muscle tissue. J Virol. 1998;72:8568\u201377.","journal-title":"J Virol"},{"key":"218_CR36","doi-asserted-by":"crossref","unstructured":"M\u00fcller OJ, Kaul F, Weitzman MD, Pasqualini R, Arap W, Kleinschmidt JA, et al. Random peptide libraries displayed on adeno-associated virus to select for targeted gene therapy vectors. Nat Biotechnol. 2003;21:1040\u20136.","DOI":"10.1038\/nbt856"},{"key":"218_CR37","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1006\/mthe.2001.0424","volume":"4","author":"SA Nicklin","year":"2001","unstructured":"Nicklin SA, Buening H, Dishart KL, De Alwis M, Girod A, Hacker U, et al. Efficient and selective AAV2-mediated gene transfer directed to human vascular endothelial cells. Mol Ther. 2001;4:174\u201381.","journal-title":"Mol Ther"},{"key":"218_CR38","doi-asserted-by":"crossref","unstructured":"Konishi M, Kawamoto K, Izumikawa M, Kuriyama H, Yamashita T. Isolation of targeted AAV2 vectors from novel virus display libraries. J Gene Med. 2008;8:1307\u201319.","DOI":"10.1002\/jgm.967"},{"key":"218_CR39","doi-asserted-by":"publisher","first-page":"443","DOI":"10.1038\/sj.gt.3303077","volume":"15","author":"K White","year":"2008","unstructured":"White K, B\u00fcning H, Kritz A, Janicki H, McVey J, Perabo L, et al. Engineering adeno-associated virus 2 vectors for targeted gene delivery to atherosclerotic lesions. Gene Ther. 2008;15:443\u201351.","journal-title":"Gene Ther"},{"key":"218_CR40","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1161\/01.CIR.0000109697.68832.5D","volume":"109","author":"SJ White","year":"2004","unstructured":"White SJ, Nicklin SA, B\u00fcning H, Brosnan MJ, Leike K, Papadakis ED, et al. Targeted gene delivery to vascular tissue in vivo by tropism-modified adeno-associated virus vectors. Circulation. 2004;109:513\u20139.","journal-title":"Circulation"},{"key":"218_CR41","doi-asserted-by":"publisher","first-page":"1073","DOI":"10.1038\/mt.2008.76","volume":"16","author":"C Zincarelli","year":"2008","unstructured":"Zincarelli C, Soltys S, Rengo G, Rabinowitz JE. Analysis of AAV serotypes 1-9 mediated gene expression and tropism in mice after systemic injection. Mol Ther. 2008;16:1073\u201380.","journal-title":"Mol Ther"},{"key":"218_CR42","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1006\/mthe.2000.0075","volume":"1","author":"CH Miao","year":"2000","unstructured":"Miao CH, Ohashi K, Patijn GA, Meuse L, Ye X, Thompson AR, et al. Inclusion of the hepatic locus control region, an Intron, and untranslated region increases and stabilizes hepatic factor IX gene expression in vivo but not in vitro. Mol Ther. 2000;1:522\u201332.","journal-title":"Mol Ther"},{"key":"218_CR43","doi-asserted-by":"publisher","first-page":"eaam6375","DOI":"10.1126\/scitranslmed.aam6375","volume":"9","author":"F Puzzo","year":"2017","unstructured":"Puzzo F, Colella P, Biferi MG, Bali D, Paulk NK, Vidal P, et al. Rescue of Pompe disease in mice by AAV-mediated liver delivery of secretable acid \u03b1-glucosidase. Sci Transl Med. 2017;9:eaam6375.","journal-title":"Sci Transl Med"},{"key":"218_CR44","first-page":"EREP02","volume":"88","author":"AB Federici","year":"2003","unstructured":"Federici AB. The factor VIII\/von Willebrand factor complex: basic and clinical issues. Haematologica. 2003;88:EREP02.","journal-title":"Haematologica"},{"key":"218_CR45","doi-asserted-by":"publisher","first-page":"5033","DOI":"10.1182\/blood-2010-09-267492","volume":"117","author":"KM Valentijn","year":"2011","unstructured":"Valentijn KM, Sadler JE, Valentijn JA, Voorberg J, Eikenboom J. Functional architecture of Weibel-Palade bodies. Blood. 2011;117:5033\u201343.","journal-title":"Blood"},{"key":"218_CR46","doi-asserted-by":"publisher","first-page":"9468","DOI":"10.1128\/JVI.73.11.9468-9477.1999","volume":"73","author":"J Yang","year":"1999","unstructured":"Yang J, Zhou W, Zhang Y, Zidon T, Ritchie T, Engelhardt JF. Concatamerization of adeno-associated virus circular genomes occurs through intermolecular recombination. J Virol. 1999;73:9468\u201377.","journal-title":"J Virol"}],"container-title":["Gene Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41434-020-00218-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41434-020-00218-6","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41434-020-00218-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,4,19]],"date-time":"2023-04-19T02:03:25Z","timestamp":1681869805000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41434-020-00218-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,17]]},"references-count":46,"journal-issue":{"issue":"3-4","published-print":{"date-parts":[[2023,4]]}},"alternative-id":["218"],"URL":"https:\/\/doi.org\/10.1038\/s41434-020-00218-6","relation":{},"ISSN":["0969-7128","1476-5462"],"issn-type":[{"value":"0969-7128","type":"print"},{"value":"1476-5462","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,17]]},"assertion":[{"value":"23 June 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 November 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 December 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 January 2021","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"FM is an employee of Spark Therapeutics. The other authors declare that they have no conflict of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}